默克公司价值数十亿美元的KEYTRUDA通过新型皮下注射提高了水平，与静脉注射的有效性相匹配-动脉网

Merck’s Multiillion-Dollar KEYTRUDA Levels Up with Novel Subcutaneous Delivery, Matching IV Effectiveness

GeneOnline 等信源发布 2024-11-22 18:03



可切换为仅中文







by Bernice Lottering

作者：Bernice Lottering

Share To

共享给

Merck's Phase 3 clinical trial demonstrated that the subcutaneous form of pembrolizumab (brand name KEYTRUDA), when combined with berahyaluronidase alfa (a substance developed by Alteogen to improve the delivery of the drug), is equally effective as the IV form of KEYTRUDA in treating metastatic lung cancer.

默克公司的3期临床试验表明，皮下形式的pembrolizumab（品牌KEYTRUDA）与berahyaluronidase alfa（Alteogen开发用于改善药物输送的物质）联合使用时，与IV形式的KEYTRUDA治疗转移性肺癌同样有效。

Essentially, the subcutaneous version of the drug performs just as well as the IV form, which could offer a more convenient method of administration for patients. Image: iStockRecently, Merck & Co. (NYSE:MRK) announced results from its Phase 3 trial of subcutaneous pembrolizumab with berahyaluronidase alfa.

基本上，该药物的皮下形式与IV形式一样好，这可以为患者提供更方便的给药方法。图片：iStock最近，默克公司（纽约证券交易所代码：MRK）宣布了皮下注射pembrolizumab和贝拉呋喃糖苷酶alfa的3期试验结果。

The study tested its effectiveness alongside chemotherapy against the intravenous KEYTRUDA formulation in metastatic lung cancer patients. APembrolizumab, marketed as KEYTRUDA, is currently available as an IV treatment. Berahyaluronidase alfa, developed by Alteogen Inc., enhances subcutaneous delivery. Phase III MK-3475A-D77 Trial Confirms Subcutaneous KEYTRUDA Matches IV Formulation in Metastatic NSCLC TreatmentMerck is aiming to extend KEYTRUDA’s dominance with promising Phase III results for a new subcutaneous formulation.

该研究在转移性肺癌患者中测试了其与静脉注射KEYTRUDA制剂化疗的有效性。APembrolizumab，以KEYTRUDA销售，目前可作为IV治疗。。III期MK-3475A-D77试验证实皮下KEYTRUDA与转移性NSCLC治疗中的IV制剂相匹配Merck旨在扩大KEYTRUDA的优势，并为新的皮下制剂提供有希望的III期结果。

The randomized, open-label Phase 3 trial, named MK-3475A-D77 (NCT05722015), combined subcutaneous KEYTRUDA with Alteogen’s berahyaluronidase alfa to facilitate under-the-skin delivery alongside chemotherapy. This was compared to the intravenous (IV) version of KEYTRUDA with chemotherapy in first-line metastatic non-small cell lung cancer (NSCLC) patients.

这项名为MK-3475A-D77（NCT05722015）的随机开放标签3期临床试验将皮下KEYTRUDA与Alteogen的berahyaluronidase alfa联合使用，以促进皮下给药和化疗。这与一线转移性非小细胞肺癌（NSCLC）患者静脉注射（IV）版本的KEYTRUDA联合化疗进行了比较。

The study met its primary endpoint, demonstrating that subcutaneous KEYTRUDA matches the IV formulation when administered every six weeks. Additionally, safety and efficacy goals were achieved, showcasing the potential of this new delivery method.Subcutaneous KEYTRUDA: A Strategic Move Amid.

该研究达到了其主要终点，证明每六周给药一次皮下KEYTRUDA与IV制剂相匹配。此外，实现了安全性和有效性目标，展示了这种新递送方法的潜力。皮下KEYTRUDA：一项战略性举措。

Sen-Jam’s First-in-Class FDA-Regulated Hangover Cure Enters Phase 2 TrialsChina’s Laekna Joins Forces with Weight-Loss Giant Lilly on Muscle-Preserving Obesity Drug in Expanding $150B MarketNovartis Invests $745M to Compete with BMS and Lilly in the Radiopharma Race

森·贾姆（Sen Jam）首创FDA监管的宿醉治疗进入第二阶段试验中国莱克纳（Laekna）与减肥巨头礼来（Lilly）联手开发肌肉保护肥胖药物，扩大了1500亿美元的市场诺华（Novartis）投资7.45亿美元，与BMS和礼来（Lilly）在放射性药物竞赛中展开竞争

Author

作者

Bernice Lottering

伯尼斯彩票